ETF Holdings Breakdown of BBIO

News associated with BBIO

BridgeBio Pharma (NASDAQ:BBIO) Given New $54.00 Price Target at Bank of America

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective raised by equities researchers at Bank of America from $50.00 to $54.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 19.68% from the […] - 2025-06-27 05:28:43

BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by analysts at HC Wainwright from $53.00 to $56.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.69% from the company’s previous […] - 2025-06-11 05:44:48

California State Teachers Retirement System Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,655 shares of the company’s stock after buying an additional 7,388 shares during the quarter. […] - 2025-06-05 09:18:53

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Mackenzie Financial Corp

Mackenzie Financial Corp increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,505 shares of the company’s stock after purchasing an additional 592 shares during the […] - 2025-06-05 08:26:59

Dimensional Fund Advisors LP Reduces Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Dimensional Fund Advisors LP cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.7% during the 4th quarter, Holdings Channel reports. The fund owned 61,665 shares of the company’s stock after selling 1,036 shares during the period. Dimensional Fund Advisors LP’s holdings in BridgeBio Pharma were worth $1,692,000 as of its most […] - 2025-05-15 07:32:47

Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $57.09

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The […] - 2025-05-14 05:34:53

Envestnet Asset Management Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Envestnet Asset Management Inc. reduced its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 18.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,926 shares of the company’s stock after selling 2,949 shares during the period. Envestnet Asset Management Inc.’s holdings in BridgeBio Pharma were worth $355,000 at the end of […] - 2025-05-06 07:22:45

BridgeBio Pharma (NASDAQ:BBIO) Reaches New 1-Year High After Better-Than-Expected Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shares reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $39.54 and last traded at $38.48, with a volume of 2185851 shares. The stock had previously closed at $36.42. The company reported ($0.88) earnings […] - 2025-05-02 05:09:05

BridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) saw some unusual options trading activity on Monday. Stock investors purchased 5,930 put options on the company. This is an increase of 67% compared to the typical volume of 3,542 put options. Wall Street Analysts Forecast Growth A number of equities research analysts have commented on the […] - 2025-04-30 07:24:51

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Legal & General Group Plc

Legal & General Group Plc increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 134,038 shares of the company’s stock after acquiring an additional 3,706 shares […] - 2025-04-23 08:21:00

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Prudential Financial Inc.

Prudential Financial Inc. reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 24.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,429 shares of the company’s stock after selling 3,360 shares during the period. Prudential Financial Inc.’s holdings in BridgeBio […] - 2025-04-11 08:02:57

Vanguard Group Inc. Buys 879,059 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Vanguard Group Inc. raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,077,915 shares of the company’s stock after purchasing an additional 879,059 shares during the period. Vanguard […] - 2025-04-03 07:37:03

KLP Kapitalforvaltning AS Makes New $692,000 Investment in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

KLP Kapitalforvaltning AS bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,235 shares of the company’s stock, valued at approximately $692,000. Several other hedge funds also recently made […] - 2025-04-02 08:08:54

BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Redburn Atlantic

Equities research analysts at Redburn Atlantic began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $50.00 price target on the stock. Redburn Atlantic’s target price suggests a potential upside of 51.42% from the company’s current […] - 2025-04-02 05:27:06

American Century Companies Inc. Boosts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

American Century Companies Inc. lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,015,728 shares of the company’s stock after purchasing an additional 88,882 shares during the quarter. American […] - 2025-03-30 09:42:56

Teacher Retirement System of Texas Purchases 8,048 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Teacher Retirement System of Texas grew its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 28.6% in the fourth quarter, HoldingsChannel.com reports. The fund owned 36,208 shares of the company’s stock after buying an additional 8,048 shares during the period. Teacher Retirement System of Texas’ holdings in BridgeBio Pharma were worth $994,000 as […] - 2025-03-30 08:50:46

BridgeBio Pharma (NASDAQ:BBIO) Trading 8.9% Higher Following Analyst Upgrade

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shot up 8.9% during trading on Monday after JPMorgan Chase & Co. raised their price target on the stock from $44.00 to $50.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. BridgeBio Pharma traded as high as $37.59 and last traded […] - 2025-03-26 05:54:42

13,155 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Cibc World Markets Corp

Cibc World Markets Corp bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,155 shares of the company’s stock, valued at approximately $361,000. Several other institutional investors […] - 2025-03-25 08:08:49

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $51.67 Consensus Price Target from Brokerages

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. The average 1-year target price […] - 2025-02-28 06:26:55

Pre-Market Most Active for Feb 26, 2025 : LCID, TSLL, SMCI, NVDA, PLTR, BBIO, BABA, NIO, QBTS, LYG, BBAI, ZETA

The NASDAQ 100 Pre-Market Indicator is up 173.63 to 21,260.88. The total Pre-Market volume is currently 120,885,751 shares traded.The following are the most active stocks for the pre-market session: Lucid Group, Inc. (LCID) is -0.2201 at $2.39, with 10,116,440 shares traded. LCI - 2025-02-26 13:29:54

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $52.00

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target hoisted by Scotiabank from $49.00 to $52.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a sector outperform rating on the stock. Several other brokerages also recently weighed in on BBIO. Evercore ISI upped their price objective on BridgeBio […] - 2025-02-24 06:29:05

BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $49.00

BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target lifted by Citigroup from $45.00 to $49.00 in a research report released on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other research analysts also recently commented on the stock. Bank of America increased their target price […] - 2025-02-24 06:29:03

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Position Raised by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 21.6% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 93,131 shares of the company’s stock after buying an additional 16,545 shares during the quarter. State of New […] - 2025-02-21 10:35:04

Mirae Asset Global Investments Co. Ltd. Has $176,000 Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Mirae Asset Global Investments Co. Ltd. cut its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 7.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,298 shares of the company’s stock after selling 503 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in BridgeBio Pharma […] - 2025-02-14 09:04:54

BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 5.5% Following Insider Selling

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shares fell 5.5% during trading on Monday following insider selling activity. The company traded as low as $32.48 and last traded at $32.33. 1,082,052 shares traded hands during trading, a decline of 61% from the average session volume of 2,802,673 shares. The stock had previously closed at […] - 2025-02-05 06:42:54

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $49.00 Average PT from Analysts

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) has been given a consensus rating of “Moderate Buy” by the thirteen ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 12-month price target among […] - 2025-02-03 06:24:55

BBIO institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	86,621	USD 3,908,340 1.6%
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	23,768	USD 1,072,412
2025-06-19	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	177,509	USD 7,100,360
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	94,755	USD 4,275,346
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	94,755	USD 4,275,346
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	598	USD 26,982
2025-06-26	IE0009VWHAE6 (iShares US Equity Enhanced Active UCITS ETF USD (Acc))	2,919	USD 131,705
Total =		480,925	USD 20,790,491

Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer